Annexon/$ANNX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Annexon

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Ticker

$ANNX
Primary listing

Industry

Biotechnology

Employees

106

ISIN

US03589W1027

Annexon Metrics

BasicAdvanced
$307M
-
-$1.16
1.24
-

What the Analysts think about Annexon

Analyst ratings (Buy, Hold, Sell) for Annexon stock.

Bulls say / Bears say

Annexon's lead candidate, ANX005, demonstrated significant efficacy in a Phase 3 trial for Guillain-Barré Syndrome, showing a 2.4-fold higher likelihood of improved health at Week 8 compared to placebo. (stocktitan.net)
Analysts have assigned a consensus 'Buy' rating to Annexon, with an average 12-month price target of $15.80, indicating strong confidence in the company's growth potential. (americanbankingnews.com)
Director William H. Carson increased his stake in Annexon by purchasing 3,200 shares, signaling insider confidence in the company's future prospects. (investing.com)
Annexon's stock has declined by 53.4% year-to-date, reflecting investor concerns over the company's financial performance. (marketbeat.com)
The company reported a net loss of $167.38 million over the trailing twelve months, raising questions about its path to profitability. (stockanalysis.com)
Annexon's stock price is currently 78.60% below its 52-week high, indicating significant market volatility and potential investor skepticism. (investchronicle.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.

Annexon Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Annexon Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ANNX

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs